|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:naltrexone
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:associatedWith
|
gptkb:Depade
gptkb:Revia
|
|
gptkbp:ATCCode
|
gptkb:N07BB04
|
|
gptkbp:brand
|
gptkb:naltrexone
|
|
gptkbp:CASNumber
|
16676-29-2
|
|
gptkbp:chemicalFormula
|
C20H23NO4
|
|
gptkbp:contraindication
|
liver failure
acute hepatitis
current opioid use
|
|
gptkbp:countryOfOperation
|
gptkb:Russia
gptkb:United_States
|
|
gptkbp:drugClass
|
opioid
|
|
gptkbp:duration
|
about 1 month
|
|
gptkbp:form
|
extended-release injectable suspension
|
|
gptkbp:halfLife
|
5-10 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vivitrol
|
|
gptkbp:interactsWith
|
gptkb:opioid_analgesics
gptkb:disulfiram
gptkb:thioridazine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Alkermes
|
|
gptkbp:marketedAs
|
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
blocks opioid receptors
|
|
gptkbp:MedlinePlusID
|
a607049
|
|
gptkbp:MeSH_ID
|
D009376
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:riskOfPrecipitatedWithdrawal
|
yes
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:RxNorm
|
59782
|
|
gptkbp:sideEffect
|
nausea
fatigue
headache
injection site reaction
hepatotoxicity
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:treatment
|
monthly
|
|
gptkbp:UNII
|
5NGC7Q0B2N
|
|
gptkbp:usedFor
|
alcohol dependence
opioid dependence
|
|
gptkbp:website
|
https://www.vivitrol.com/
|
|
gptkbp:bfsParent
|
gptkb:Naltrexone
|
|
gptkbp:bfsLayer
|
6
|